This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of California, San Francisco

CTRI/2025/11/097895

/ Not yet recruitingNot ApplicableIIT

To evaluate efficacy and safety of Ixekizumab in Indian Psoriasis Patients. - nil

Start Date18 Dec 2025

Sponsor / Collaborator-

CTIS2022-503119-40-00

/ Not yet recruitingPhase 3

Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-groups, randomised controlled trial

Start Date01 Dec 2025

Sponsor / Collaborator

Azienda Ospedaliera Ordine Mauriziano Di Torino

100 Clinical Results associated with Ixekizumab

100 Translational Medicine associated with Ixekizumab

100 Patents (Medical) associated with Ixekizumab

1,119

Literatures (Medical) associated with Ixekizumab

01 Feb 2026·Rheumatology and Therapy

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials

Article

Author: Lisse, Jeffrey ; Magrey, Marina ; Gibble, Theresa Hunter ; Rahman, Proton ; Park, So Young ; Rudwaleit, Martin ; Reveille, John D ; Kronbergs, Andris ; Bolce, Rebecca ; Ng, Khai Jing ; Navarro-Compán, Victoria ; Maldonado-Cocco, Jose A

INTRODUCTION:

The human leukocyte antigen (HLA)-B27 is associated with axial spondyloarthritis (axSpA) and is a predictor of response to tumor necrosis factor inhibitors. However, limited data are available on HLA-B27 and interleukin-17 inhibitors. We evaluated the influence of HLA-B27 status on ixekizumab response through 52 weeks in patients with axSpA.

METHODS:

Data were analyzed from three randomized placebo-controlled trials: COAST-V (NCT02696785), COAST-W (NCT02696798), and COAST-X (NCT02757352). Patients fulfilled the Assessment of SpondyloArthritis international Society (ASAS) criteria for radiographic (r)-axSpA or non-radiographic (nr)-axSpA. Patients were randomized to receive 80 mg ixekizumab every 2 weeks, 80 mg ixekizumab every 4 weeks, or placebo. This post hoc analysis assessed the intent-to-treat population. The magnitude of benefit was calculated as the value for ixekizumab minus placebo.

RESULTS:

Among ixekizumab-treated patients with r-axSpA at week 16, ASAS ≥ 40% improvement (ASAS40) was achieved by 39.6% (n = 118/298) of HLA-B27-positive and 29.3% (n = 12/41) of HLA-B27-negative patients. The magnitude of benefit (ixekizumab-placebo) was 23.5% for HLA-B27-positive and 15.2% for HLA-B27-negative patients. At week 52, 44% of HLA-B27-positive and 31.7% of HLA-B27-negative patients achieved ASAS40. Similar trends were seen for Axial Spondyloarthritis Disease Activity Score low disease activity (ASDAS LDA; < 2.1) and Bath Ankylosing Spondylitis Disease Activity Index ≥ 50% improvement (BASDAI50). In ixekizumab-treated patients with nr-axSpA at week 16, ASAS40 response was achieved by 41.7% (n = 55/132) of HLA-B27-positive and 28.0% (n = 14/50) of HLA-B27-negative patients. The magnitude of benefit was 19.2% for HLA-B27-positive and 16.0% for HLA-B27-negative patients. At week 52, 52.3% of HLA-B27-positive and 32.0% of HLA-B27-negative patients achieved ASAS40. Similar trends were seen among patients with nr-axSpA for ASDAS LDA and BASDAI50.

CONCLUSIONS:

In patients with r-axSpA and nr-axSpA, ixekizumab improved response through 52 weeks for both HLA-B27-positive and HLA-B27-negative patients. However, the magnitude of benefit for ixekizumab versus placebo was numerically greater for HLA-B27-positive patients.

TRIAL REGISTRATION:

ClinicalTrials.gov identifiers, NCT02696785, NCT02696798, and NCT02757352.

02 Jan 2026·MEDICINE

Secukinumab compared to ixekizumab in biologic-naïve Chinese individuals afflicted with moderate-to-severe plaque psoriasis: A retrospective single-center analysis

Article

Author: Zhao, Dayu

The clinical benefits of interleukin (IL)-17A therapies for psoriasis are well-substantiated. However, efficacy outcomes for moderate-to-severe plaque psoriasis (pPS) may vary across IL-17A treatments. Practitioners require evidence to guide treatment selection within the IL-17A class for biologic-naïve patients with moderate-to-severe pPS. This study compares the effectiveness and safety of ixekizumab and secukinumab in such patients. A retrospective analysis of 5 years of electronic medical records (demographics, clinical characteristics, treatment outcomes, and adverse effects) was conducted on biologic-naïve patients receiving IL-17A treatments for moderate-to-severe stable pPS. The study comprised 70 ixekizumab users (ET cohort) and 55 secukinumab users (SB cohort) from a single center. Concurrent therapies were evenly distributed across groups. Both cohorts exhibited significant reductions in percentage body surface area involvement and Psoriasis Area and Severity Index scores posttreatment ( P < .001 for all). However, the SB cohort demonstrated greater reductions in percentage body surface area involvement ( P < .001) and Psoriasis Area and Severity Index scores compared with the ET cohort. Physician Global Assessment of treatment response favored the SB cohort (1.1 [1.4–1] vs 1.1 [1.5–1]). Systemic organ infections were more prevalent in the SB cohort ( P = .009). Following treatment, 26 (37%) and 24 (44%) patients in the ET and SB cohorts, respectively, achieved mild disease activity (≤1 on Physician Global Assessment). The SB cohort experienced a higher incidence of adverse effects ( P < .001, risk ratio = 0.52; 95% confidence interval = 0.37–0.73, I2 = 0%). In Chinese biologic-naïve patients with moderate-to-severe pPS, secukinumab may be associated with a superior response but a higher incidence of adverse effects compared with ixekizumab.

02 Jan 2026·MEDICINE

New-onset ulcerative colitis temporally associated with with ixekizumab in a psoriasis patient successfully treated with guselkunmab: A case report

Article

Author: Zhang, Haiyan ; Tang, Jing ; Li, Wenjuan

Rationale::

Ulcerative colitis (UC) and psoriasis are both chronic inflammatory diseases mediated by the immune system. Ixekizumab, used to treat psoriasis, carries a risk of inducing or exacerbating UC. Infliximab has also been reported to exacerbate psoriasis. Guselkumab (GUS) can be used to treat both UC and psoriasis. Currently, there are few case reports on the use of GUS for the treatment of UC–psoriasis comorbidity. Our observations support the rationale for IL-23–targeted agents in patients with overlapping psoriasis and inflammatory bowel disease, and they provide exploratory evidence that the psoriasis-labeled regimen of GUS may suffice for selected UC patients.

Patient concerns::

A 51-year-old woman with a history of psoriasis for more than 20 years was diagnosed with ulcerative colitis due to abdominal pain, diarrhea, and mucous-bloody stools while using ixekizumab. During treatment with infliximab for ulcerative colitis, her psoriatic lesions worsened. Switching to guselkumab achieved complete skin clearance (PASI 0) and sustained endoscopic remission of UC (Mayo 1, UCEIS 1) without the need for additional biologic therapy.

Diagnoses::

Psoriasis has been previously diagnosed; ulcerative colitis was diagnosed based on the patient’s clinical symptoms, colonoscopy, and pathological examination.

Interventions::

The patient was given guselkumab (100 mg every 8 weeks) and mesalazine (4 g every day).

Outcomes::

Four months after starting guselkumab, the patient’s psoriasis area and severity index score reached 0, and guselkumab therapy was continued thereafter. Since then, she has experienced no gastrointestinal symptoms, and her psoriasis has been well-controlled. On June 28, 2025, a follow-up colonoscopy was performed. The Mayo endoscopic score was 1, and the ulcerative colitis endoscopic index of severity score was 1.

Lessons::

Dermatologists closely monitor gastrointestinal symptoms in patients with psoriasis who are receiving ixekizumab to ensure safe medication use. Patients with ulcerative colitis and psoriasis may actively consider using guselkumab.

118

News (Medical) associated with Ixekizumab

26 Jan 2026

·www.biospace.com

Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results

In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year history Excluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion INCHEON, Korea--(BUSINESS WIRE)-- #ADCs --Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically investing in our future pipeline with a disciplined, long-term approach. We aim to drive sustainable growth and create long-term value for our shareholders, so that we can remain committed to improving patient access worldwide.” Samsung Bioepis Fourth Quarter & Fiscal Year 2025 Results In the fourth quarter of 2025, Samsung Bioepis achieved a consolidated revenue of KRW 429.4 billion with an operating profit of KRW 29.2 billion. Revenue and operating profit based on product sales (excluding milestone revenue) in the fourth quarter increased by 23% and 14% year-over-year (YoY), respectively. Full-year 2025 (FY2025) revenue reached KRW 1.672 trillion (+9%) while operating profit stood at KRW 375.9 billion (-14%). Excluding milestone revenue, sales revenue and operating profit stood at KRW 1.626 trillion (+28%) and KRW 330.8 billion (+101%), respectively. [Consolidated Earnings, KRW billion] Q4’23 Q4’24 Q4’25 YoY Change FY23 FY24 FY25 YoY Change Revenue 288.9 397.4 429.4 +32.0 1 (+8%) 1,020.3 1,537.7 1,672.0 +134.3 1 (+9%) Excluding Milestone Revenue 288.9 347.0 425.2 +78.2 (+23%) 1,008.3 1,266.8 1,626.9 +360.1 (+28%) Operating Profit 78.2 72.3 29.2 -43.1 (-60%) 205.4 435.4 375.9 -59.5 (-14%) Excluding Milestone Revenue 78.2 21.9 25.0 +3.1 (+14%) 193.4 164.5 330.8 +166.3 (+101%) The growth was driven by Samsung Bioepis’ continued global expansion through product launches, regulatory approvals, and new partnerships. EPYSQLI™ (SB12), a biosimilar to Soliris 2 (eculizumab), indicated for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and generalized Myasthenia Gravis (gMG), was launched in the United States (US) in April 2025 through its commercialization partner Teva Pharmaceuticals, improving access for patients with rare diseases. OBODENCE™ / OSPOMYV™ 3 (SB16), a biosimilar to Prolia 4 (denosumab), and XBRYK™ (SB16), a biosimilar to Xgeva 3 (denosumab), were approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) in February 2025. In Europe, OBODENCE was launched in December 2025, consequently followed by the launch of XBRYK in January 2026. As of January 2026, four products are directly commercialized by Samsung Bioepis in Europe, namely EPYSQLI (eculizumab), OBODENCE (denosumab), XBRYK (denosumab), and BYOOVIZ™ (ranibizumab). 5 PYZCHIVA™ (SB17), a biosimilar to Stelara 6 (ustekinumab), was launched in the US in partnership with Sandoz in February 2025. PYZCHIVA has also been available as private label brands since the second and third quarter of 2025. In Japan, SB17 was approved as Ustekinumab BS Subcutaneous Injection 45mg Syringes 「NIPRO」 by Pharmaceuticals and Medical Devices Agency (PMDA) in December 2025. It is the first product to gain marketing approval in Japan under the partnership with NIPRO CORPORATION entered in June 2025. Samsung Bioepis entered into a partnership agreement with Harrow for commercialization of BYOOVIZ (SB11), a biosimilar referencing Lucentis 7 (ranibizumab) and OPUVIZ™ (SB15), a biosimilar referencing Eylea 8 (aflibercept), in the US. Fiscal Year 2026 Outlook Samsung Epis Holdings is actively supporting its subsidiaries' core businesses under the holding company structure, with a goal of increasing global biosimilar sales by more than 10% compared YoY. Samsung Bioepis plans to secure 20 biosimilars in its portfolio by 2030, including dupilumab, guselkumab, ixekizumab, trastuzumab deruxtecan, vedolizumab, and ocrelizumab. Beyond biosimilars, the company has also embarked on its novel therapeutic development. It plans to have one novel therapeutic candidate enter into clinical study every year, starting with SBE303. SBE303 is Samsung Bioepis’ first novel antibody-drug conjugate (ADC) engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including bladder cancer, urothelial cancer, lung cancer, and breast cancer. 9 The Phase 1 first-in-human clinical trial, aiming to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of SBE303 in participants with advanced refractory solid tumors, is set to begin this year. Epis NexLab, the new subsidiary under Samsung Epis Holdings, has launched a project to develop a peptide-based drug delivery platform. About Samsung Epis Holdings Co., Ltd. As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: . About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit and follow us on LinkedIn and X . About Epis NexLab Co., Ltd. Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: . 1 The year-over-year (YoY) change in operating profit is reflective of the ‘milestone payment’ – a payment system that pays out upon completion of specific milestones within a project’s development. 2 Soliris is a trademark of Alexion Pharmaceuticals, Inc. 3 SB16 was approved under different names in Europe and the US; OBODENCE in Europe and OSPOMYV in the US 4 Prolia and Xgeva are trademarks of Amgen Inc. 5 In Europe, Samsung Bioepis has assumed full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. 6 Stelara is a trademark of Johnson & Johnson Corporation. 7 Lucentis is a trademark of Genentech Inc. 8 Eylea is a trademark of Regeneron Pharmaceuticals, Inc 9 Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101. Contacts Media Contact Yoon Kim, yoon1.kim@samsung.com Anna Nayun Kim, nayun86.kim@samsung.com

Drug ApprovalPhase 1

15 Jan 2026

·www.biospace.com

Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference

Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studies Having secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this year Samsung Bioepis plans to add one novel therapeutic candidate in clinical study every year INCHEON, Korea--(BUSINESS WIRE)-- #ADC --Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. "2026 is a monumental year for us, as we enter into a new chapter for our company. Today, we are announcing six additional candidates in our biosimilar pipeline, including vedolizumab and dupilumab. We are making great progress to secure 20 biosimilars in our portfolio by 2030," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We also received the investigational new drug application (IND) clearance for the first novel therapeutic candidate developed by Samsung Bioepis, and plan to advance our clinical program this year. As we broaden our portfolio beyond biosimilars, we will continue our development efforts in antibody-drug conjugates (ADCs), leveraging our innovative research and development platform to expand viable treatment options for patients with unmet needs.” Samsung Bioepis Biosimilar Updates Samsung Bioepis currently has 11 biosimilars for 10 unique biological molecules approved and launched in more than 40 countries. 1 The company has pembrolizumab biosimilar undergoing Phase 1 and 3 clinical studies, and plans to secure 20 biosimilars in its portfolio by 2030. The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab. Novel Therapeutics Updates In December 2025, the FDA has cleared the IND Application for SBE303. SBE303 is Samsung Bioepis’ first novel ADC engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer. 2 The Phase 1 first-in-human clinical trial, aiming to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of SBE303 in participants with advanced refractory solid tumors, is set to begin this year. Samsung Bioepis plans to have one novel therapeutic candidate enter into clinical study every year. Epis NexLab, the new subsidiary under Samsung Epis Holdings, has launched a project to develop a peptide-based drug delivery platform. Samsung Bioepis Biosimilars Portfolio Code Name (Brand Name 3 ) Non-proprietary Name Reference Product Status 4 SB5 (IMRALDI™, HADLIMA™, ADALLOCE™) Adalimumab Humira Launch SB4 (BENEPALI™, BRENZYS™, ETOLOCE™) Etanercept Enbrel Launch SB2 (FLIXABI™, RENFLEXIS™, REMALOCE™) Infliximab Remicade Launch SB3 (ONTRUZANT™, SAMFENET™) Trastuzumab Herceptin Launch SB8 (AYBINTIO™) Bevacizumab Avastin Launch SB11 (BYOOVIZ™, AMELIVU™) Ranibizumab Lucentis Launch SB12 (EPYSQLI™) Eculizumab Soliris Launch SB15 (OPUVIZ™, AFILIVU™) Aflibercept Eylea Launch SB16 (OBODENCE™, OSPOMYV™) Denosumab Prolia Launch SB16 (XBRYK™) Denosumab Xgeva Launch SB17 (PYZCHIVA™, EPYZTEK™) Ustekinumab Stelara Launch SB27 Pembrolizumab Keytruda Phase 1 and 3 Samsung Bioepis Biosimilar Candidates in Early Stage Development Non-proprietary Name Reference Product Dupilumab Dupixent Guselkumab Tremfya Ixekizumab Taltz Vedolizumab Entyvio Ocrelizumab Ocrevus Fam-trastuzumab deruxtecan-nxki Enhertu About Samsung Epis Holdings Co., Ltd. As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings aims to maximize corporate and shareholder value through proactive R&D and investment and optimize business strategies for its subsidiaries, Samsung Bioepis and Epis NexLab. Samsung Epis Holdings continues to embrace future challenges and drive innovation by identifying new growth drivers and strengthening global collaboration platforms, thereby laying a solid foundation for the continued growth of its subsidiaries. For more information about Samsung Epis Holdings, please visit: . About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit and follow us on LinkedIn and X . About Epis NexLab Co., Ltd. Established in 2025 as a 100% owned subsidiary of Samsung Epis Holdings, Epis NexLab is committed to driving innovation through the development of next-generation biotechnology platforms. By transforming highly scalable peptide-related technologies into development platforms, Epis NexLab is focused on the discovery of innovative treatment modalities for the development of multiple therapeutic candidates targeting a wide range of diseases. For more information about Epis NexLab, please visit: . 1 “more than 40 countries” signifies countries where Samsung Bioepis has commercial presence, with one or more products. 2 Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101. 3 Different brand names for different regions and countries. 4 “Launch” signifies launch in one or more markets and does not necessarily indicate launch in all markets worldwide Contacts Media Contact Anna Nayun Kim, nayun86.kim@samsung.com Yoon Kim, yoon1.kim@samsung.com

Phase 1INDADC

09 Jan 2026

·www.biopharmadive.com

Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal

Today, a brief rundown of news from Insmed and Johnson & Johnson, as well as updates from Madrigal Pharmaceuticals, Moonlake Immunotherapeutics, Eli Lilly and Lexeo Therapeutics that you may have missed.Insmed said that Brinsupri, its recently approved drug for a chronic lung condition, generated close to $145 million in sales in its first full quarter on the market. Brinsupri is used to treat bronchiectasis not caused by cystic fibrosis and widely expected by Wall Street analysts to generate billions in sales. Still, the numbers announced Friday more than doubled consensus estimates and were hailed by multiple analysts as a ginormous, impressiveresult that could further heighten expectations. Analysts currently project $723 million in 2026 alone, but those estimates may now be approaching $1 billion, wrote RBC Capital Markets Leonid Timashev. Ben FidlerJohnson & Johnson on Thursday became the latest pharmaceutical company to agree to most favored nation pricing in return for a reprieve on pharmaceutical tariffs. The company didnt provide many specifics in its announcement. But itll participate in a government online channel for drug purchasing; enable U.S. patients to access drugs at comparable prices to whats paid in foreign countries; and give the same prices to Medicaid, which already has best-price guarantees. J&J will also build a cell therapy plant in Pennsylvania and a facility in North Carolina as part of its $55 billion commitment to boost U.S. manufacturing capacity. Jonathan GardnerMadrigal Pharmaceuticals said Friday it licensed from Pfizera drug it sees becoming part of a potential combination regimen involving its marketed MASH drug Rezdiffra.Pfizer received $50 million upfront for the therapy, ervogastat, and is entitled to unspecified additional milestone payments and royalties. Madrigal noted that the drug helped spur significant reductions of liver fat in Phase 2 testingand may boost the effects of Rezdiffra, which works via a different mechanism. Itll conduct a drug-drug interaction study and discuss the design of a Phase 2 combination trial with the Food and Drug Administration this year. Delilah Alvarado Moonlake Immunotherapeutics shares climbed by 27% on news that the company may not need to run another trial to gain FDA approval for a medication its been developing for the skin disease hidradenitis suppurativa. Moonlakes market value crumbled in September after it reported mixed results from two Phase 3 studies. But on Thursday, the company said that based on FDA feedback it may be able to prove the effectiveness of the drug, sonelokimab, with existing evidence. Itll file an application later this year. Ben FidlerA combination of Eli Lillys obesity drug Zepboundand autoimmune medication Taltz was better than Taltz alone at spurring weight loss andreducing signs of psoriatic arthritis in a Phase 3 trial, the company said Thursday. The trial enrolled people with the inflammatory condition and who are overweight or have obesity. Investigators found that 32% of enrollees who got both drugs saw a 50% reduction in psoriatic arthritis activity and at least 10% loss of body weight over 36 weeks, compared with less than 1% in those who got just Taltz. Lilly said it will discuss the results with global health regulators. Jonathan GardnerLexeo Therapeutics and J&J will work on a new way to deliver gene therapies to the heart,the companies said Thursday. Through the deal, the companies will use a type of heart pump technology known as Impella to more directly send adeno-associated viruses into cardiac tissue. They hope to show that the approach might enhance efficacy and safety, in part by enabling companies use lower doses of AAVs, which can trigger potentially dangerous immune responses. Delilah Alvarado '

Clinical ResultPhase 3Gene TherapyPhase 2Drug Approval

100 Deals associated with Ixekizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10071	Ixekizumab	L04AC13	DB11569

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spondylarthritis	Canada	Eli Lilly & Co.	11 Aug 2016
Erythrodermic psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Psoriasis vulgaris	Japan	Eli Lilly Japan KK	04 Jul 2016
Pustular psoriasis	Japan	Eli Lilly Japan KK	04 Jul 2016
Ankylosing Spondylitis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Ankylosing Spondylitis	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Arthritis, Psoriatic	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Axial Spondyloarthritis	Norway	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	European Union	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	Iceland	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016
Non-radiographic axial spondyloarthritis	Liechtenstein	Eli Lilly & Company (Ireland) Ltd.	25 Apr 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enthesitis-Related Arthritis	NDA/BLA	European Union	Eli Lilly & Company (Ireland) Ltd.	24 Jul 2025
Juvenile Idiopathic Arthritis	NDA/BLA	European Union	Eli Lilly & Company (Ireland) Ltd.	24 Jul 2025
Obesity	Phase 3	United States	Eli Lilly & Co.	24 Sep 2024
Chronic large plaque psoriasis	Phase 3	United States	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Japan	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Australia	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Canada	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Denmark	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Germany	Eli Lilly & Co.	16 Nov 2011
Chronic large plaque psoriasis	Phase 3	Hungary	Eli Lilly & Co.	16 Nov 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06588296 (TOGETHER-PsA, Company_Website) Manual	Phase 3	Arthritis, Psoriatic \| Overweight \| Obesity	271	Taltz (ixekizumab) + Zepbound (tirzepatide)	ufsmngryyj(tdbeuanuef) = himoxwuufa smyayqixxi (tfvuhdiftf ) Met View more	Superior	08 Jan 2026
				Taltz (ixekizumab)	ufsmngryyj(tdbeuanuef) = mezfxuxsal smyayqixxi (tfvuhdiftf ) Met View more
ACR2025	Not Applicable	Psoriasis \| Ankylosing Spondylitis	181,052	Secukinumab	tojiagkgnn(jsflvjukfa) = aynpqhuosg iewbcltabc (nessxkqncz ) View more	Positive	24 Oct 2025
ACR2025	Not Applicable	Arthritis, Psoriatic	237	risankizumabguselkumabab + risankizumabguselkumab	ychgwmiizq(kyftxtvbkj) = cgimvpizal eeczmanbbf (emsfxjahgw )	Positive	24 Oct 2025
NCT05855967 (CTgov)	Phase 4	Plaque psoriasis \| Arthritis, Psoriatic	250	Ixekizumab (Ixekizumab - PsO With no Active PsA)	ahhufmygoo = zmleoljhtn jighofdbjd (uewkmvtveu, ibgvoocvji - uukrywzwcu) View more	-	22 Aug 2025
				Ixekizumab (Ixekizumab - Active PsA)	ysefkstwnb = yjfvfoocgx xirsxawdpt (azricvdfkj, amrrinrmcq - klqfjpcobq)
NCT02696785 (COAST-X, Pubmed \| Adv Ther)	Phase 3	Axial Spondyloarthritis	513	Ixekizumab (r-axSpA + shorter symptom duration)	teqesoqsau(mknnrhgrli) = xicrpyuxso kijjahbfiu (oddvkjqqsa ) View more	Positive	22 Jul 2025
				Ixekizumab (r-axSpA + longer symptom duration)	teqesoqsau(mknnrhgrli) = jhujrgxpct kijjahbfiu (oddvkjqqsa ) View more
ESPADA (EULAR2025)	Not Applicable	Axial Spondyloarthritis	106	Ixekizumab	qvwmsaqypm(wwvkkgpmsi) = gixlbhhrqc zldhpurtnj (yvvlvgvbsa ) View more	Positive	11 Jun 2025
NCT04527380 (CTgov)	Phase 3	Enthesitis-Related Arthritis \| Juvenile Idiopathic Arthritis \| Ankylosing Spondylitis	101	Ixekizumab (Ixekizumab - OLT Period)	wkpcoxkbiq = nfjqcjgevp mjfxtonupw (mxvwghowhz, qkndhmtmpj - cazujxqfhj) View more	-	05 Jun 2025
				Adalimumab (Adalimumab - OLT Period)	euzhlaazsu = ccftwomdby hdqlcdicfp (fdzudajiec, vnphyeczmc - qzkbszxybe) View more
NCT04979910 (CTgov)	Phase 2	Depressive Disorder, Major \| Depressive Disorder, Treatment-Resistant	7	Ixekizumab	rsafjnxfhf = emzzwgjoot anjzlqjbof (cvzihfdgvd, sdhnvyyeop - tonleymcxf) View more	-	20 May 2025
NCT04285229 (Pubmed \| Rheumatol Ther)	Phase 3	Axial Spondyloarthritis C-reactive protein level	147	Ixekizumab 80 mg every 4 weeks	rwhhfbthxk(bxfybejoyh) = qwbpspskum zozimyvgwd (slwtyqtylr )	Positive	09 May 2025
				Placebo	rwhhfbthxk(bxfybejoyh) = ngabpapubi zozimyvgwd (slwtyqtylr )
NCT03364309 (Phase 3 Trial, Pubmed \| Adv Ther)	Phase 3	Psoriasis	289	Ixekizumab	udztvvftjl(gomrhlxfyy) = AEs were comparable in patients who received continuous treatment and retreatment fckkjszpms (cpmmxlkcol )	Positive	13 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis